M Peeters1, G Kafatos2, A Taylor2, V M Gastanaga3, K S Oliner4, G Hechmati5, J-H Terwey6, J H van Krieken7. 1. Department of Oncology, Antwerp University Hospital, Wilrijkstraat 10, B-2650 Edegem, Belgium. Electronic address: Marc.Peeters@uza.be. 2. Center for Observational Research, Amgen Ltd, 1 Uxbridge Business Park, Sanderson Road, Uxbridge UB8 1DH, UK. 3. Center for Observational Research, Amgen Inc, One Amgen Center Drive, Thousand Oaks, CA 91329-1799, USA. 4. Medical Sciences, Amgen Inc, One Amgen Center Drive, Thousand Oaks, CA 91329-1799, USA. 5. Health Economics, Amgen (Europe) GmbH, Dammstrasse 23, Opus 105, Zug 6301, Switzerland. 6. Medical Development, Amgen (Europe) GmbH, Zählerweg 6, Opus 192, Zug 6301, Switzerland. 7. Radboud University Nijmegen Medical Center, P.O. Box 9101, 6500 HB Nijmegen (911), The Netherlands.
Abstract
BACKGROUND: The use of epidermal growth factor receptor inhibitors to treat metastatic colorectal cancer (mCRC) patients requires prior confirmation of tumour wild type (WT) RAS mutation status (exons 2/3/4 for KRAS or NRAS). This retrospective pooled analysis aims to robustly estimate RAS mutation prevalence and individual variation patterns in mCRC patients. METHOD: Individual patient data from five randomised, controlled panitumumab studies (three phase III, one phase II and one phase Ib/II) were pooled for this analysis. The phase III studies included mCRC patients independent of RAS mutation status; the phase II and Ib/II studies included mCRC patients with confirmed WT KRAS exon 2 status. Four studies conducted RAS testing using Sanger sequencing; one study used a combination of next-generation sequencing and Sanger sequencing. In order to assign overall RAS status, the mutation status of all exons 2/3/4 KRAS or NRAS was required to be known. RESULTS: Data from 3196 mCRC patients from 36 countries were included in the analysis. The overall unadjusted RAS mutation prevalence in mCRC patients was 55.9% (95% confidence interval (CI): [53.9-57.9%]), with the following distribution observed: KRAS exon 2 (prevalence 42.6% [40.7-44.5%]); KRAS exon 3 (3.8% [2.9-4.9%]); KRAS exon 4 (6.2% [5.0-7.6%]); NRAS exon 2 (2.9% [2.1-3.9%]); NRAS exon 3 (4.2% [3.2-5.4%]); NRAS exon 4 (0.3% [0.1-0.7%]). Differences in RAS mutation prevalence estimates were observed by study (p=0.001), gender (p=0.030), and by country (p=0.028). CONCLUSIONS: This analysis provides robust estimates of overall RAS mutation prevalence and individual variation patterns in mCRC patients.
BACKGROUND: The use of epidermal growth factor receptor inhibitors to treat metastatic colorectal cancer (mCRC) patients requires prior confirmation of tumour wild type (WT) RAS mutation status (exons 2/3/4 for KRAS or NRAS). This retrospective pooled analysis aims to robustly estimate RAS mutation prevalence and individual variation patterns in mCRC patients. METHOD: Individual patient data from five randomised, controlled panitumumab studies (three phase III, one phase II and one phase Ib/II) were pooled for this analysis. The phase III studies included mCRC patients independent of RAS mutation status; the phase II and Ib/II studies included mCRC patients with confirmed WT KRAS exon 2 status. Four studies conducted RAS testing using Sanger sequencing; one study used a combination of next-generation sequencing and Sanger sequencing. In order to assign overall RAS status, the mutation status of all exons 2/3/4 KRAS or NRAS was required to be known. RESULTS: Data from 3196 mCRC patients from 36 countries were included in the analysis. The overall unadjusted RAS mutation prevalence in mCRC patients was 55.9% (95% confidence interval (CI): [53.9-57.9%]), with the following distribution observed: KRAS exon 2 (prevalence 42.6% [40.7-44.5%]); KRAS exon 3 (3.8% [2.9-4.9%]); KRAS exon 4 (6.2% [5.0-7.6%]); NRAS exon 2 (2.9% [2.1-3.9%]); NRAS exon 3 (4.2% [3.2-5.4%]); NRAS exon 4 (0.3% [0.1-0.7%]). Differences in RAS mutation prevalence estimates were observed by study (p=0.001), gender (p=0.030), and by country (p=0.028). CONCLUSIONS: This analysis provides robust estimates of overall RAS mutation prevalence and individual variation patterns in mCRC patients.
Authors: Michael Levi; Gintang Prayogi; Farid Sastranagara; Edi Sudianto; Grace Widjajahakim; Winiarti Gani; Albert Mahanadi; Jocelyn Agnes; Bela Haifa Khairunisa; Ahmad R Utomo Journal: J Gastrointest Cancer Date: 2018-06
Authors: Jonathan M Loree; Yucai Wang; Muddassir A Syed; Alexey V Sorokin; Oluwadara Coker; Joanne Xiu; Benjamin A Weinberg; Ari M Vanderwalde; Anteneh Tesfaye; Victoria M Raymond; Benjamin Miron; Gabi Tarcic; Ori Zelichov; Russell R Broaddus; Patrick Kwok Shing Ng; Kang Jin Jeong; Yiu Huen Tsang; Gordon B Mills; Michael J Overman; Axel Grothey; John L Marshall; Scott Kopetz Journal: Clin Cancer Res Date: 2021-06-11 Impact factor: 12.531
Authors: Wânia Cristina da Silva; Brian Godman; Francisco de Assis Acúrcio; Mariângela Leal Cherchiglia; Antony Martin; Konrad Maruszczyk; Jans Bastos Izidoro; Marcos André Portella; Agner Pereira Lana; Orozimbo Henriques Campos Neto; Eli Iola Gurgel Andrade Journal: Appl Health Econ Health Policy Date: 2021-01-28 Impact factor: 2.561
Authors: Rebecca A Snyder; Jun He; Jennifer Le-Rademacher; Fang-Shu Ou; Andrew B Dodge; Tyler J Zemla; Electra D Paskett; George J Chang; Federico Innocenti; Charles Blanke; Heinz-Josef Lenz; Blasé N Polite; Alan P Venook Journal: Cancer Date: 2021-08-10 Impact factor: 6.921